Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon
VP-VEC-162-3108
Phase 3 small_molecule active
Quick answer
Placebo liquid formulation will be indistinguishable from its tasimelteon counterpart and will be administered in the same way., Tasimelteon for Insomnia Disorder is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Insomnia Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active